52-week Open Label Safety-Tolerability Study

Evaluate long term safety and tolerability of LB-102 by evaluating the number of adverse event, incidence of treatment emergent events.

Overall adverse events, serious adverse events, incidence of treatment emergent events and adverse events which lead to study discontinuation

Evaluate long term safety and tolerability

Evaluating the safety of treatment by number of adverse events

Evaluate long term safety and tolerability

Evaluating the safety of treatment by change in vital signs, electrocardiogram (QTC), and weight/height for BMI

Evaluate long term safety and tolerability

Evaluating the safety of treatment by conducting physical examinations

Assess the long-term effectiveness determined by Positive and Negative Syndrome Scale (PANSS)

Change in Positive and Negative Syndrome Scale (PANSS) from Baseline to end of treatment where a decrease in score likely indicate response to treatment whereas an increase in score may indicate a worsening of disease where an increase in the scale score may indicate a worsening of disease and decrease in score likely indicates response to treatment.